Market Research Report
Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Size, Share & Trends Analysis Report By Procedure (Transapical, Transfemoral, Transaortic), By Country, Vendor Landscape, And Segment Forecasts, 2018 - 2025
|Published by||Grand View Research, Inc.||Product code||666020|
|Published||Content info||90 Pages
Delivery time: 2-3 business days
|Transcatheter Aortic Valve Replacement/Implantation (TAVR/TAVI) Market Size, Share & Trends Analysis Report By Procedure (Transapical, Transfemoral, Transaortic), By Country, Vendor Landscape, And Segment Forecasts, 2018 - 2025|
|Published: June 13, 2018||Content info: 90 Pages||
The global transcatheter aortic valve replacement (TAVR) devices market size is anticipated to reach USD 12.2 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 22.6% during the forecast period. Increasing incidence of cardiovascular diseases and severe aortic stenosis disorder are among key factors augmenting the TAVR device market. Moreover, rising number of various clinical trials such as Edwards SAPIEN 3 and Medtronic Transcatheter Aortic Valve 2.0 Replacement System are likely to contribute to the growth of the market during the forecast period.
Improvements in surgical techniques and quality of implantable valves are leading to an increase in the adoption of aortic valve replacement procedures. Moreover, surging demand for minimally invasive surgeries as compared to traditional open heart procedures, availability of reimbursement for surgical procedures, and growing inclination of physicians towards TAVR procedures are projected to boost the growth of the market.
Launch of new devices with advanced technology for fast and effective treatment is poised to propel the market. For instance, in April 2016, St. Jude Medical launched a new device - Trifecta Valve with glide technology to be used in both conventional as well as minimally invasive procedures.
Some of the key players in the market are: Medtronic plc; Boston Scientific Corporation; Meril Life Sciences Pvt. Ltd., Inc.; Edwards Lifesciences Corporation; St. Jude Medical, Inc.; JenaValve Technology, Inc.; Bracco SpA; and Transcatheter Technologies GmbH.